Department of Psychiatry, The Royal's Institute of Mental Health Research, University of Ottawa, Ottawa, ON, Canada.
Department of Psychoeducation and Psychology, Université du Québec en Outaouais, Gatineau, QC, Canada.
Psychol Med. 2024 Jun;54(8):1835-1843. doi: 10.1017/S003329172300380X. Epub 2024 Feb 15.
Enlarged pituitary gland volume could be a marker of psychotic disorders. However, previous studies report conflicting results. To better understand the role of the pituitary gland in psychosis, we examined a large transdiagnostic sample of individuals with psychotic disorders.
The study included 751 participants (174 with schizophrenia, 114 with schizoaffective disorder, 167 with psychotic bipolar disorder, and 296 healthy controls) across six sites in the Bipolar-Schizophrenia Network on Intermediate Phenotypes consortium. Structural magnetic resonance images were obtained, and pituitary gland volumes were measured using the MAGeT brain algorithm. Linear mixed models examined between-group differences with controls and among patient subgroups based on diagnosis, as well as how pituitary volumes were associated with symptom severity, cognitive function, antipsychotic dose, and illness duration.
Mean pituitary gland volume did not significantly differ between patients and controls. No significant effect of diagnosis was observed. Larger pituitary gland volume was associated with greater symptom severity ( = 13.61, = 0.0002), lower cognitive function ( = 4.76, = 0.03), and higher antipsychotic dose ( = 5.20, = 0.02). Illness duration was not significantly associated with pituitary gland volume. When all variables were considered, only symptom severity significantly predicted pituitary gland volume ( = 7.54, = 0.006).
Although pituitary volumes were not increased in psychotic disorders, larger size may be a marker associated with more severe symptoms in the progression of psychosis. This finding helps clarify previous inconsistent reports and highlights the need for further research into pituitary gland-related factors in individuals with psychosis.
垂体体积增大可能是精神障碍的标志物。然而,先前的研究报告结果相互矛盾。为了更好地理解垂体在精神疾病中的作用,我们检查了一个患有精神障碍的大样本的跨诊断个体。
该研究包括来自六个双相情感障碍-精神分裂症网络中间表型联盟研究中心的 751 名参与者(174 名精神分裂症患者、114 名精神分裂情感障碍患者、167 名精神病性双相障碍患者和 296 名健康对照者)。采集结构磁共振图像,使用 MAGeT 大脑算法测量垂体体积。线性混合模型根据诊断检查了组间差异,以及根据诊断的患者亚组之间的差异,以及垂体体积与症状严重程度、认知功能、抗精神病药物剂量和疾病持续时间之间的关系。
患者和对照组之间的垂体体积无显著差异。未观察到诊断的显著影响。更大的垂体体积与更严重的症状相关( = 13.61, = 0.0002)、更低的认知功能( = 4.76, = 0.03)和更高的抗精神病药物剂量( = 5.20, = 0.02)。疾病持续时间与垂体体积无显著相关性。当考虑所有变量时,只有症状严重程度显著预测垂体体积( = 7.54, = 0.006)。
尽管精神障碍患者的垂体体积没有增加,但更大的体积可能是精神病进展中与更严重症状相关的标志物。这一发现有助于澄清先前不一致的报告,并强调需要进一步研究精神疾病个体中与垂体相关的因素。